Published 2017
| Version v1
Publication
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program
- Creators
- Andreoni M.
- Teti E.
- Antinori A.
- Milazzoi L.
- Sollima S.
- Rizzardini G.
- Di Biagio A.
- Saracino A.
- Bruno R.
- Borghi V.
- De Luca A.
- Cattelan A.
- Hasson H.
- Taliani G.
- Monforte A. D.
- Mastroianni C. M.
- Di Perri G.
- Bigoni S.
- Puoti M.
- Spinetti A.
- Gori A.
- Boffa N.
- Cacopardo B.
- Giacometti A.
- Parruti G.
- Vullo V.
- Chirianni A.
- Pennica A.
- Pasquazzi C.
- Segala D.
- Sarmati L.
- Others:
- Andreoni, M.
- Teti, E.
- Antinori, A.
- Milazzoi, L.
- Sollima, S.
- Rizzardini, G.
- Di Biagio, A.
- Saracino, A.
- Bruno, R.
- Borghi, V.
- De Luca, A.
- Cattelan, A.
- Hasson, H.
- Taliani, G.
- Monforte, A. D.
- Mastroianni, C. M.
- Di Perri, G.
- Bigoni, S.
- Puoti, M.
- Spinetti, A.
- Gori, A.
- Boffa, N.
- Cacopardo, B.
- Giacometti, A.
- Parruti, G.
- Vullo, V.
- Chirianni, A.
- Pennica, A.
- Pasquazzi, C.
- Segala, D.
- Sarmati, L.
Description
Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/ paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).
Additional details
- URL
- http://hdl.handle.net/11567/995772
- URN
- urn:oai:iris.unige.it:11567/995772
- Origin repository
- UNIGE